Esophageal Diseases – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Esophageal Diseases – Drugs In Development, 2023’, provides an overview of the Esophageal Diseases pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Diseases and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Esophageal Diseases
- The report reviews pipeline therapeutics for Esophageal Diseases by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Diseases therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Diseases therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Diseases
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Diseases
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Diseases pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adare Pharma SolutionsAddpharma Inc
Ahn-Gook Pharmaceutical Co Ltd
Akeso Inc
Amgen Inc
Amytrx Therapeutics Inc
Aqilion AB
Astellas Pharma Inc
Banner Life Sciences LLC
Bioprojet SCR
Bristol-Myers Squibb Co
CalyGene Biotechnology Inc
Calypso Biotech SA
Celldex Therapeutics Inc
Cellix Bio Pvt Ltd
Changchun Haiyue Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp.
Cinclus Pharma Holding AB
CSL Ltd
Daehan New Pharm Co Ltd
Daewoong Co Ltd
Delta 4 GmbH
Dr. Falk Pharma GmbH
Eisai Co Ltd
Ellodi Pharmaceuticals
EsoCap AG
Eupraxia Pharmaceuticals Inc
Genuone Science Co Ltd
GSK plc
Hana Pharm Co Ltd
Harvard Apparatus Regenerative Technology Inc
Harway Pharma Co Ltd
HK inno.N Corp
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Invea Therapeutics Inc
ISOThrive Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Sinorda Biomedicine Co Ltd
JSR Life Sciences LLC
JW Pharmaceutical Corp
Korea Pharma Co Ltd
Korea United Pharm Inc
Kymera Therapeutics Inc
Lanier Biotherapeutics Inc
Lexeo Therapeutics Inc
Luoxin Pharmaceuticals Group Stock Co Ltd
Morphic Therapeutic Inc
NImmune Biopharma Inc
Onconic Therapeutics Co Ltd
Palo BioFarma SL
Pantherics Inc
Pfizer Inc
Phathom Pharmaceuticals Inc
Quorum Innovations LLC
R-Pharm
RAPT Therapeutics Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
Renexxion LLC
Revolo Biotherapeutics Ltd
Sebela Pharmaceuticals Inc
Seelos Therapeutics
Inc.
Serpin Pharma LLC
Shanghai Haini Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Suzhou Connect Biopharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Trio Medicines Ltd
University of Pittsburgh
Ventyx Biosciences Inc
Xiamen Encheng Pharmaceutical Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zein Biotechnology Co Ltd
Zeria Pharmaceutical Co Ltd